Alembic Pharma in India reports a nearly seven-fold increase in Q4 earnings due to Robust Sales

Alembic Pharmaceuticals Ltd, an Indian generic drugmaker, announced a nearly seven-fold increase in fourth-quarter profit on Friday, aided by decreased expenses and high revenues from its domestic drug-making sector. The firm, which makes Wikoryl cough and cold pills, said its consolidated earnings increased to 1.53 billion rupees ($18.60 million) for the three months ended March 31, up from 219.2 million rupees a year earlier. However, income for the Azithral manufacturer declined 0.7%.

Its total expenses fell 7.4%, the first fall in the previous four quarters.For the past three quarters, the company's revenue has increased sequentially, aided by strength in its domestic medication manufacturing sector and fast-growing active pharmaceutical ingredients (API) division. Higher expenses, on the other hand, have knocked on its profit and margins.

APIs are biologically active components of a medicine that aid in the desired health benefits. Meanwhile, Glenmark Life Sciences Ltd, which competes with Alembic Pharma's API business, reported a 48% increase in fourth-quarter profit last week. Cipla Ltd, Lupin Ltd, and Dr Reddy's Laboratories Ltd, Alembic Pharma's larger peers, are slated to publish their quarterly results next week. PEERS COMPARISON Estimated valuations (next 12 months) Analyst sentiment (next 12 months) Revenue Profit RIC PE EV/EBI Analysts' price yield projection for the mean of stock to Div TDA growth Alembicicals Limited Cipla Limited Lupin Limited Dr. Reddy's Enterprises Ltd.